MLV & Co. upgraded Cytokinetics (NASDAQ: CYTK) from Hold to Buy with a price target of $9.00.

For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.

Shares of Cytokinetics closed at $3.70 yesterday.